Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA120432
Max Phase: Preclinical
Molecular Formula: C28H28ClN5O3
Molecular Weight: 518.02
Molecule Type: Small molecule
Associated Items:
ID: ALA120432
Max Phase: Preclinical
Molecular Formula: C28H28ClN5O3
Molecular Weight: 518.02
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1cc(-c2c(OCC[C@@H]3CCN3)c3cc(C(=O)Nc4ccncn4)c(Cl)cc3[nH]c2=O)cc(C)c1C
Standard InChI: InChI=1S/C28H28ClN5O3/c1-15-10-18(11-16(2)17(15)3)25-26(37-9-6-19-4-8-31-19)21-12-20(22(29)13-23(21)33-28(25)36)27(35)34-24-5-7-30-14-32-24/h5,7,10-14,19,31H,4,6,8-9H2,1-3H3,(H,33,36)(H,30,32,34,35)/t19-/m0/s1
Standard InChI Key: XESORVDKNANWAB-IBGZPJMESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 518.02 | Molecular Weight (Monoisotopic): 517.1881 | AlogP: 4.95 | #Rotatable Bonds: 7 |
Polar Surface Area: 109.00 | Molecular Species: BASE | HBA: 6 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 8 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 11.84 | CX Basic pKa: 10.59 | CX LogP: 3.96 | CX LogD: 1.24 |
Aromatic Rings: 4 | Heavy Atoms: 37 | QED Weighted: 0.32 | Np Likeness Score: -0.80 |
1. Guo Z, Chen Y, Wu D, Zhu YF, Struthers RS, Saunders J, Xie Q, Chen C.. (2003) Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidine-2,4-dione derivatives as potent GnRH receptor antagonists., 13 (20): [PMID:14505682] [10.1016/s0960-894x(03)00746-7] |
2. DeVita RJ, Walsh TF, Young JR, Jiang J, Ujjainwalla F, Toupence RB, Parikh M, Huang SX, Fair JA, Goulet MT, Wyvratt MJ, Lo JL, Ren N, Yudkovitz JB, Yang YT, Cheng K, Cui J, Mount G, Rohrer SP, Schaeffer JM, Rhodes L, Drisko JE, McGowan E, MacIntyre DE, Vincent S, Carlin JR, Cameron J, Smith RG.. (2001) A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptor., 44 (6): [PMID:11300873] [10.1021/jm000275p] |
3. Tucci FC, Zhu YF, Struthers RS, Guo Z, Gross TD, Rowbottom MW, Acevedo O, Gao Y, Saunders J, Xie Q, Reinhart GJ, Liu XJ, Ling N, Bonneville AK, Chen T, Bozigian H, Chen C.. (2005) 3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization., 48 (4): [PMID:15715483] [10.1021/jm049218c] |
4. DeVita RJ, Parikh M, Jiang J, Fair JA, Young JR, Walsh TF, Goulet MT, Lo JL, Ren N, Yudkovitz JB, Cui J, Yang YT, Cheng K, Rohrer SP, Wyvratt MJ.. (2004) Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists., 14 (22): [PMID:15482932] [10.1016/j.bmcl.2004.08.056] |
5. Betz SF, Zhu YF, Chen C, Struthers RS.. (2008) Non-peptide gonadotropin-releasing hormone receptor antagonists., 51 (12): [PMID:18419112] [10.1021/jm701249f] |
Source(1):